This Oncology API Stock Rises 125% in 1 Year: From January Lows to Record Highs

This oncology API stock has risen approximately 125% in one year, from Rs 417.40 on 10 September 2025 to Rs 939.90 on 10 September 2026, placing it among the top 31 performers on a screen of 195 NSE small-cap stocks dated 11 September 2026. The climb did not come in a straight line: the oncology API stock first slid to a low near Rs 259.50 in January 2026 and then more than tripled on the back of record earnings, European approvals and a biosimilar deal in immuno-oncology.

The company is Shilpa Medicare Ltd (NSE: SHILPAMED), a Raichur-based maker of cancer drug ingredients, finished formulations and biologics. The Shilpa Medicare share price closed at Rs 939.90 on 10 September 2026 and traded around Rs 945 in early trade on 11 September, giving the company a market value of approximately Rs 18,390 crore.

Click Here – Get Free Investment Predictions

How Much Has This Oncology API Stock Returned?

The oncology API stock returned approximately 125.2% over one year on bonus-adjusted closing prices. All periods below are measured to the 10 September 2026 close.

Period	Price Return (%)
1 Month	Approximately 16.4%
6 Months	Approximately 177.5%
1 Year	Approximately 125.2%
3 Years	Approximately 405.9%
5 Years	Approximately 208.4%

The company issued bonus shares in the ratio of 1:1 with a record date of 3 October 2025, which falls inside the 1-year window. Every return above uses bonus-adjusted prices, so the gain in this oncology API stock is real, not a bonus artifact.

The 52-week range runs from Rs 259.50, touched in the last week of January 2026, to Rs 980.10, hit on 7 September 2026. The oncology API stock is now about 4% below that high but roughly 3.6 times its January low. The 5-year return trails the 3-year figure because the oncology API stock fell sharply through 2022 and early 2023 before its recovery began.

Why Did This Oncology API Stock Rise So Sharply?

The oncology API stock rose because earnings turned a corner, with net profit more than tripling in FY26 and doubling again in the June 2026 quarter. European product approvals, a biosimilar partnership for a blockbuster cancer drug and a credit rating upgrade added fuel, and the stock re-rated from a depressed base.

1. A Profit Turnaround After Weak Years

Through FY23 and FY24, this oncology API stock was held back by thin profits and heavy spending on biologics. It posted a net loss of about Rs 31 crore in FY23 and a profit of only about Rs 32 crore in FY24.

That changed in FY26 for the oncology API stock. Revenue rose about 18% to approximately Rs 1,549 crore, and net profit rose to approximately Rs 243 crore from about Rs 78 crore in FY25. Management put adjusted return on capital employed at 17.4% for FY26, up from 4% in FY23.

2. Record Quarters Kept Coming

The December 2025 quarter brought revenue of about Rs 411 crore, up 28% year on year. The March 2026 quarter was stronger, with revenue up about 32% and net profit of approximately Rs 108 crore against about Rs 15 crore a year earlier. The oncology API stock rose about 4% to Rs 493.10 on results day in May 2026.

The biggest single jump came on 5 August 2026. Revenue for the June 2026 quarter rose about 43% to approximately Rs 469 crore, EBITDA rose 42% to about Rs 139 crore and net profit more than doubled to approximately Rs 101 crore. The oncology API stock rose about 11.6% that day and more than 24% over the week.

3. Oncology API Sales Remain the Backbone

The API business, built largely around cancer drug ingredients, earned about Rs 985 crore in FY26, up 16%. Management credited new oncology products for much of that growth. In the June 2026 quarter, API revenue grew about 15% to approximately Rs 260 crore, helped by in-house formulation demand and a growing specialty contract manufacturing book.

This steady base funds newer bets at the oncology API stock. Operating cash flow rose to approximately Rs 342 crore in FY26 from about Rs 132 crore a year earlier.

4. Formulations Doubled on European Launches

Formulations revenue doubled year on year in the June 2026 quarter to approximately Rs 198 crore. Europe contributed about Rs 57 crore, the US about Rs 45 crore and India about Rs 24 crore. The company won European approval for Rivaroxaban orodispersible films in September 2025 and for a Rotigotine transdermal patch in December 2025.

In India, the company launched NorUDCA in the December 2025 quarter, a first-of-its-kind fatty liver therapy. Management said it has order book visibility for the product in FY27, with European and other markets planned later.

5. Biosimilar Deal in Immuno-Oncology

At the end of June 2026, subsidiary Shilpa Biologicals signed a co-development and supply agreement with Finnish drugmaker Orion for an intravenous nivolumab biosimilar. Orion gets exclusive European rights, while Shilpa will develop and manufacture the product at its Dharwad facility and earn milestone payments plus supply revenue. The oncology API stock touched a then 52-week high of Rs 608.80 on the news.

Biologics revenue roughly doubled to about Rs 150 crore in FY26. In June 2026 the group also commissioned an antibody-drug conjugate facility in Dharwad and took a stake in Spanish biotech Gate2Brain.

6. Rating Upgrade and Lower Debt

After the June 2026 quarter, the credit rating was upgraded to AA- from A+. Debt to equity has fallen to 0.25 from 0.48 in FY24, and the balance sheet shows equity of approximately Rs 2,591 crore. For an oncology API stock that spends heavily on capacity, lower funding costs matter.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

Shilpa Medicare Share Price: Quarterly Financial Performance

Revenue at the oncology API stock has grown in each of the last five quarters, with EBITDA margins near 30%. This consistency is the main reason the Shilpa Medicare share price has re-rated.

Quarter	Revenue (Rs Cr)	EBITDA (Rs Cr)	Net Profit (Rs Cr)	Net Margin
Jun 2025	327.84	98.01	46.89	14.59%
Sep 2025	371.72	110.03	44.07	11.91%
Dec 2025	410.54	115.11	44.58	13.16%
Mar 2026	438.66	121.38	107.79	19.54%
Jun 2026	468.91	139.40	100.88	21.66%

One caution applies to the latest quarter. Management said the tax rate in the June 2026 quarter was negative because of a deferred tax liability reversal, and it expects the rate to normalise at around 25% from here. Profit before tax was about Rs 98 crore, so the underlying profit run-rate is lower than the headline Rs 101 crore suggests.

For the oncology API stock, the next test is whether 40% revenue growth lasts once European launches are in the base.

Who Owns This Oncology API Stock?

Promoters hold 40.13% of the oncology API stock, and institutions together own about 19.4%. The promoter figure dropped from 44.23% in December 2025 because two family members were reclassified from promoter to public with shareholder approval, not because promoters sold shares in the market.

Quarter	Promoters	FII	DII	Public
Jun 2025	44.23%	11.20%	7.46%	37.12%
Sep 2025	44.23%	10.92%	7.67%	37.18%
Dec 2025	40.13%	10.97%	8.33%	40.56%
Mar 2026	40.13%	11.08%	8.58%	40.21%
Jun 2026	40.13%	11.38%	8.05%	40.43%

Foreign holding has edged up to 11.38% in June 2026 from 10.92% in September 2025. Domestic institutional holding rose to 8.58% in March 2026 before easing to 8.05% in June. Small-cap, healthcare and tax saver mutual funds hold the oncology API stock, along with a life insurer.

Valuation: Is This Oncology API Stock Expensive Now?

Yes, on trailing earnings the oncology API stock trades at a premium. The Shilpa Medicare share trades at a PE of approximately 61.9 against an industry PE of about 38, and at approximately 7.1 times book value. Debt to equity is 0.25, EPS over the trailing twelve months is Rs 15.20 and the dividend yield is only 0.06%.

Return on equity of 9.39% is modest for a stock at seven times book. Buyers of the oncology API stock are paying for profit growth expected from biologics, peptides and European formulations, not for current returns on capital.

Key Risks for This Oncology API Stock

The main risks are a stretched valuation, execution on a crowded pipeline, regulatory events in the US and Europe, and the sharp price swings that come with a small cap.

Valuation and Profit Normalisation

With a PE near 62, the oncology API stock needs strong growth to justify its price. As the tax rate normalises to around 25%, reported profit could look slower, and a quarter that misses expectations could hit the stock hard.

Regulatory and Legal Events

In August 2026, the company started a voluntary Class II recall of about 27,923 vials of a chemotherapy drug in the US. In December 2025, a Delhi High Court order restrained it from making Ruxolitinib products in a patent dispute, though the company said the product was used only for research.

US formulation revenue growth has also been flat, and the company stopped selling generic azacitidine because margins were not sustainable. Any adverse inspection at a plant serving regulated markets would weigh on the oncology API stock.

Pipeline and Capex Risk

Capital spending was approximately Rs 371 crore in FY26. Big projects at the oncology API stock, such as recombinant albumin, the nivolumab biosimilar and semaglutide, are years from meaningful revenue, and delays could hurt sentiment. Management has said continued investment may slow progress toward its 35% EBITDA margin goal.

Liquidity and Volatility

Small caps move fast in both directions. The oncology API stock fell about 38% between September 2025 and January 2026 before its rally, and it has swung by 5% to 12% in single sessions around news. Turnover in an oncology API stock of this size can thin out in weak markets, making exits harder.

Download the Univest iOS App or Univest Android App to track the Shilpa Medicare share price live

Shilpa Medicare Share: Analyst View

The Shilpa Medicare share has been rewarded for delivering record numbers four quarters in a row, but the Shilpa Medicare share price now bakes in a lot of future growth. The Q1 FY27 results show the business shifting from a pure ingredient supplier toward a mix of formulations, biologics and contract manufacturing, which could support higher margins over time.

Analysts watching the oncology API stock will focus on three things: whether formulation growth holds up after the European launches, how quickly NorUDCA scales, and whether the biosimilar and albumin programmes stay on schedule.

Shilpa Medicare Share Price Target

No verified brokerage Shilpa Medicare share price target was available at the time of writing, so investors should treat any Shilpa Medicare share price target seen online with caution. For this oncology API stock, the chart offers clearer reference levels.

On the upside, the 52-week high of Rs 980.10 is the first hurdle, and the oncology API stock is about 4% below it. On the downside, the Rs 800 to Rs 820 zone, where the stock consolidated in mid-August after results, is a nearby support area. Any future Shilpa Medicare share price target from a brokerage is likely to hinge on FY27 earnings after tax normalisation.

Other Stocks to Track From the Same Return Screen

Beyond this oncology API stock, a screen of 195 small-cap NSE stocks dated 11 September 2026 also includes related names such as Bliss GVS with a 1-year return of 358.71%, Acutaas Chemicals at 136.67% and Garware Hi-Tech Films at 107.98%.

Among the names covered from that screen, MTAR Technologies returned 396.53% over one year. Readers can compare this oncology API stock with the Nifty 50 benchmark and track each of these names on Univest before making any decision.

Conclusion

The 125% rise in this oncology API stock is backed by real earnings growth. Revenue has climbed for five straight quarters, profit has multiplied, debt has fallen and the credit rating has improved. New European products and a biosimilar deal have widened the oncology API stock story beyond cancer drug ingredients.

The risks are just as real. The Shilpa Medicare share price trades at about 62 times trailing earnings, the latest profit got a tax boost, and the oncology API stock has shown it can fall nearly 40% in a few months. Investors tracking this oncology API stock may want to watch the next two quarters closely and size positions with small-cap volatility in mind.

Frequently Asked Questions

Which oncology API stock rose 125% in 1 year?

Ans. Shilpa Medicare Ltd (NSE: SHILPAMED) is the oncology API stock that returned approximately 125% over one year to 10 September 2026 on bonus-adjusted prices. It was among the top 31 performers on a screen of 195 NSE small-cap stocks dated 11 September 2026.

Why did the Shilpa Medicare share price rise?

Ans. The Shilpa Medicare share price rose on a sharp profit turnaround, record quarterly revenue, European approvals for new formulations and a nivolumab biosimilar deal with Orion. A credit rating upgrade to AA- and lower debt also helped.

Did Shilpa Medicare issue bonus shares?

Ans. Yes, the company issued bonus shares in a 1:1 ratio with a record date of 3 October 2025. The approximately 125% return is based on bonus-adjusted prices, so it reflects a real gain for shareholders.

What were Shilpa Medicare Q1 FY27 results?

Ans. Revenue rose about 43% year on year to approximately Rs 469 crore and EBITDA rose 42% to about Rs 139 crore. Net profit more than doubled to approximately Rs 101 crore, partly helped by a deferred tax reversal.

What is the 52-week high and low of Shilpa Medicare?

Ans. The 52-week high is Rs 980.10, touched on 7 September 2026, and the 52-week low is Rs 259.50, touched in late January 2026. The share traded around Rs 945 on 11 September 2026.

Is Shilpa Medicare overvalued?

Ans. On trailing numbers it trades at a PE of about 61.9, well above the industry PE of about 38, and at around 7.1 times book value. The valuation assumes strong growth will continue, which leaves little room for disappointment.

What is the Shilpa Medicare share price target?

Ans. No verified brokerage target is available at present. Traders are watching the 52-week high of Rs 980.10 as resistance and the Rs 800 to Rs 820 zone as support.

What are the key risks for this oncology API stock?

Ans. Key risks include a stretched valuation, normalising tax rates, a recent US drug recall, a patent dispute, heavy capital spending and small-cap volatility. The stock fell about 38% between September 2025 and January 2026 before rallying.